Drug
Flotetuzumab 3 NG KG Day
Flotetuzumab 3 NG KG Day: highest development phase Phase 1/2, developed by MacroGenics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- MacroGenics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off NCT02152956 | Phase 1/2 | AML |
Latest
No recent events.
Follow Flotetuzumab 3 NG KG Day on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.